Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, December 10, 2021
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
[ Fri, Dec 10th 2021
] - WOPRAI
Aydin Huseynov Initiated (SPRB) at Buy and Held Target at $7 on, Dec 10th, 2021
Aydin Huseynov of Benchmark, Initiated "Spruce Biosciences, Inc." (SPRB) at Buy and Held Target at $7 on, Dec 10th, 2021.
Aydin has made no other calls on SPRB in the last 4 months.
There are 4 other peers that have a rating on SPRB. Out of the 4 peers that are also analyzing SPRB, 2 agree with Aydin's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Ritu Baral of "Cowen & Co." Downgraded from Buy to Hold on, Tuesday, November 23rd, 2021
- Joseph Schwartz of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $5 on, Tuesday, November 16th, 2021
These are the ratings of the 2 analyists that currently disagree with Aydin
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $6 on, Tuesday, November 16th, 2021
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, November 16th, 2021
